Compare Visa Inc (V) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Viatris Inc — how do they compare? Visa Inc trades at $361.75 (market cap $671.74B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Visa Inc is far larger — about 35.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| V | VTRS | |
|---|---|---|
Market Cap | $671.74B | $18.69B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $370.47 | $17.86 |
52-Week Low | $295.52 | $9.49 |
Enterprise Value | $682.32B | $30.80B |
Dividend Yield | 0.74% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals including a 50.78% net income margin and consistent earnings beats. Recent news highlights AI-driven commerce initiatives and stablecoin partnerships, positioning the company for future growth. The stock is near its pivot point of $361, with support at $359 and resistance at $364.
The outlook remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and high profitability support long-term value. The next earnings report on April 28, 2026, will be a key catalyst.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
